Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 11, 2026
- $719.5M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.37M in total
- 1
- 13F holdersQ2 2026, +29 vs. previous quarter
- 108
- 13F valueReported value at the end of Q2 2026
- $734.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$59.9M
- No comparable prior period
- Free cash flow, FY2025
- -$54.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 10.6M
- Shares sold short
- Change
- +827.1K
- +8.5% vs. previous
- Days to cover
- 7.76
- At average daily volume
Superinvestors holding CLYM, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding CLYM at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Climb Bio, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 17, 2026 (view filing)4:15 PM ET | Sep 15 | 2 days | Thomas Stephen BasilDirector | SSale | −100.0K | $13.67 | −$1.37M | −17.6%468.0K after | 10b5-1 |
| Jun 30, 2026 (view filing) | Jun 29 | 1 day | Brennan AoifePresident and CEO | SSale | −30.9K | $13.17 | −$407.0K | −26.0%87.7K after | 10b5-1 |
| Feb 27, 2026 (view filing) | Feb 25-26 | 2 days | Thomas Stephen BasilDirector | SSale | −50.0K | $7.00 | −$350.2K | −24.4%154.7K after | 2 lots10b5-1 |
| Feb 17, 2026 (view filing) | Feb 12-13 | 5 days | Thomas Stephen BasilDirector | SSale | −100.0K | $5.29 | −$528.8K | −32.8%204.7K after | 2 lots10b5-1 |
| Jan 7, 2026 (view filing)4:55 PM ET | Jan 5 | 2 days | RA Capital Healthcare Fund LP and 6 othersDirector, 10% Owner | PPurchase | +7.11K | $3.50 | +$24.9K | +0.2%3.40M after | |
| Dec 15, 2025 (view filing)7:55 PM ET | Dec 11-12 | 4 days | RA Capital Healthcare Fund LP and 6 othersDirector, 10% Owner | PPurchase | +314.6K | $2.40 | +$754.7K | +10.2%3.40M after | 2 lots |
| Jul 1, 2025 (view filing) | Jun 30 | 1 day | Brennan AoifePresident and CEO | SSale | −20.6K | $1.22 | −$25.2K | −30.0%48.1K after | 10b5-1 |
| Jun 20, 2025 (view filing) | Jun 20 | Same day | Pimblett EmilySVP, Finance & CAO | SSale | −1.24K | $1.24 | −$1.54K | −6.2%18.9K after | 10b5-1 |
| Mar 20, 2025 (view filing) | Mar 20 | Same day | Pimblett EmilySVP, Finance & CAO | SSale | −1.20K | $1.31 | −$1.57K | −7.3%15.1K after | 10b5-1 |
| Dec 20, 2024 (view filing) | Dec 19 | 1 day | Pimblett EmilyCHIEF ACCOUNTING OFFICER | SSale | −1.24K | $2.02 | −$2.49K | −9.8%11.3K after | 10b5-1 |
Top 10 13F holders, Q2 2026
See all 108 holdersThe largest institutional positions in Climb Bio, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 11,300,939 | $147.4M | 1.28% | 00.0% | Unchanged |
| FMR LLC | 6,790,364 | $88.5M | 0.00% | +6,783,967+106,049.2% | Added |
| UBS Group AG | 3,404,866 | $44.4M | 0.01% | +3,318,921+3,861.7% | Added |
| Braidwell LP | 2,797,375 | $36.5M | 1.35% | +1,267,700+82.9% | Added |
| Adage Capital Partners GP, L.L.C. | 2,506,000 | $32.7M | 0.05% | +2,506,000 | New |
| BlackRock, Inc. | 2,354,872 | $30.7M | 0.00% | +1,953,223+486.3% | Added |
| Price T Rowe Associates Inc | 2,127,281 | $27.7M | 0.00% | +210,313+11.0% | Added |
| Cormorant Asset Management, LP | 2,106,000 | $27.5M | 1.41% | +2,106,000 | New |
| Frontier Capital Management Co LLC | 1,939,019 | $25.3M | 0.24% | +1,939,019 | New |
| Vanguard Capital Management LLC | 1,698,654 | $22.2M | 0.00% | +519,995+44.1% | Added |
Holders of 5% or more of CLYM
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Climb Bio, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Ra Capital Management, L.P. | 13D/A | 33.00%23.9M shares | 0.00 ppfrom 33.00% | Aug 19, 202112 filings | Nov 9, 2026 | SEC |
| FMR LLC | 13G/A | 15.00%8.62M shares | +3.10 ppfrom 11.90% | Jul 8, 20262 filings | Nov 5, 2026 | SEC |
| Pontifax Management 4 G.P. (2015) Ltd. | 13G | 7.70%5.21M shares | New | Sep 18, 20251 filing | Sep 18, 2025 | SEC |
| Flynn James E | 13G | 5.25%3.07M shares | New | Oct 28, 20261 filing | Oct 28, 2026 | SEC |
| BlackRock, Inc. | 13G | 5.00%2.90M shares | New | Oct 27, 20261 filing | Oct 27, 2026 | SEC |